Lundbeck also known as H. Lundbeck A/S is a Danish international pharmaceutical company founded in 1915 and headquartered in Copenhagen, Denmark. It specializes in research, development, manufacturing, marketing, and sale of pharmaceuticals across the world.
According to reports, Lundbeck has announced plans to acquire Longboard a U.S.-based pharmaceutical for $2.6 billion USD to boost its portfolio with a potential epilepsy drug.
The report further mentions that the deal will add promising treatments to neurological conditions, particularly in the area of Developmental and Epileptic Encephalopathies (DEE), which commonly affects children. The company also estimates a global peak sale of $1.5 – $2 billion USD from Longboard lead drug, Bexicaserin which it plans to launch in the fourth quarter of 2028.
Longboard Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company, that specializes in the research and development of medicines for neurological diseases. It was founded in 2020 and is headquartered in San Diego, California.
